Alimera Data to be Featured in Scientific Programming at Upcoming Annual Congress ATLANTA, April 20, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners...

Paladin Phase 4 Study Confirms Safety of Durable ILUVIEN® Treatment and Reduces Burden of Care For DME Patients ATLANTA, July 26, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners...

Phase 4 PALADIN Study Confirms Positive Predictive Value of Corticosteroid Course Prior to ILUVIEN® Use for IOP Outcomes ATLANTA, May 12, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...

Phase 4 PALADIN Study with ILUVIEN® Published in Peer-Reviewed Journal Ophthalmology Best corrected visual acuity and central subfield thickness were significantly improved at 36 monthsILUVIEN treatment resulted in a 70.5% reduction in treatment burdenResults confirm that use of prior...

Recent 24-Month Real-World PALADIN Data Demonstrate the Ability of ILUVIEN® to Significantly Reduce Treatment Burden in Patients with Diabetic Macular Edema PALADIN Study Data Presented at the American Society of Retina Specialists Shows That Post-ILUVIEN, the Percentage of Eyes Receiving One Yearly Treatment or Less Increased 3.2-Fold Compared to...